

Special Issue

Innovations in the Treatment of Urothelial Cancer

Message from the Guest Editor

Recurrence rates for bladder cancer or upper-tract TCC remain high, with as many as 60% of patients requiring repeat treatments within 24 months, despite treatment with intravesical BCG or other chemotherapy regimens. Despite initially high response rates to treatment, recurrence rates for bladder cancer remain high. These high rates of tumor recurrence and risk of progression may explain why mortality rates for bladder cancer have decreased far less than for those observed among patients with other cancers, such as prostate, breast, lung, and colon cancer. In addition, tumor recurrence is invariably associated with the significant impairment of quality of life (QoL)-related outcomes.

With the advent of immunotherapy and other innovative treatments, the last decade has brought new hope to patients with urothelial cancer. With many novel diagnostic tools such as MRI, and with new biomarkers and treatments on the horizon, there is increased optimism that we will change the trajectory of this disease in the near future. The goal of this Special Issue is to highlight several novel avenues in the diagnosis and treatment of urothelial cancer.

Guest Editor

Prof. Dr. Gilad E. Amiel

Department of Urology, Rambam Health Care Center, Haifa 3109601, Israel

Deadline for manuscript submissions

closed (15 March 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/176863

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)